Prognostic value of a breast cancer-associated glycoprotein detected by monoclonal antibody LU-BCRU-G7.
The immunohistochemical reactivity of a second generation murine monoclonal antibody (LU-BCRU-G7), raised against a novel fucosylated glycoprotein of M(r) 2300,000, has shown a significant association with prognosis of early stage carcinomas. Staining was observed in 72% of the 190 breast carcinomas tested. No relationship with steroid receptor status, stage or node status was found. An association with grade was observed (chi 2 7.83, 2 degrees of freedom, P = 0.02) only when the negative cut-off level was raised from < 10% cells staining to < 25%. Antibody reactivity was always cytoplasmic. Immunoblotting shows the antibody is reactive with a component of M(r) 230,000 not detected by HMFG 2. A significant association was found between lack of reactivity and improved disease-free interval (0.005 > P > 0.001) and survival (0.02 > P > 0.01). Subdivision of cases on the basis of node status showed that staining could refine survival data. A decreased reactivity of LU-BCRU-G7 was observed after pretreatment with beta-galactosidase but not a sialidase or beta-N-acetylhexosaminodase indicating that non-reducing terminal galactose residues in beta 1-3 or beta 1-4 linkages may be involved in the antibody binding site. This approach has identified a useful and novel prognostic marker in early stage human breast carcinoma.
Rye
P D
PD
Department of Tumour Biology, Institute for Cancer Research, Norwegian Radium Hospital, Montebello, Oslo.
Walker
R A
RA
D000230:Adenocarcinoma / Q000737:chemistry* / Q000401:mortality; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D001940:Breast / Q000737:chemistry; D001943:Breast Neoplasms / Q000737:chemistry* / Q000401:mortality; D002277:Carcinoma / Q000737:chemistry* / Q000401:mortality; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D009364:Neoplasm Recurrence, Local; D011379:Prognosis
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D006023:Glycoproteins